Univariate analysis of clinical, histological, and molecular parameters with OS, PFS, and MPFS in 146 patients with low-grade-gliomas
| . | OS . | PFS . | MPFS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Age (modeled as continuous variable) | 1.021 | 1.003–1.040 | 0.021 | 1.008 | 0.993–1.024 | 0.287 | 1.014 | 0.997–1.030 | 0.104 |
| Sex | |||||||||
| Male | 1 | 1 | 1 | ||||||
| Female | 0.706 | 0.446–1.120 | 0.139 | 0.906 | 0.627–1.309 | 0.600 | 0.718 | 0.480–1.073 | 0.106 |
| KPS (modeled as continuous variable) | 0.963 | 0.931–0.996 | 0.027 | 0.987 | 0.957–1.018 | 0.410 | 0.970 | 0.940–1.000 | 0.052 |
| Preoperative volume (T2_pre) (modeled as continuous variable) | 1.002 | 0.998–1.006 | 0.357 | 1.003 | 1.000–1.007 | 0.071 | 1.006 | 1.002–1.009 | 0.002 |
| Infiltrative growth index (T2_ T1) (modeled as continuous variable) | 1.028 | 1.014–1.043 | <0.0001 | 1.028 | 1.015–1.042 | <0.0001 | 1.038 | 1.024–1.053 | <0.0001 |
| Postoperative (T2_post) (modeled as continuous variable) | 1.007 | 0.998–1.015 | 0.112 | 1.007 | 1.001–1.015 | 0.030 | 1.017 | 1.010–1.024 | <0.0001 |
| % EOR (modeled as continuous variable) | 0.942 | 0.926–0.959 | <0.0001 | 0.955 | 0.941–0.970 | <0.0001 | 0.951 | 0.936–0.966 | <0.0001 |
| Histotype (WHO 2007) | |||||||||
| Astrocytoma | 1 | 1 | 1 | ||||||
| Oligodendroglioma | 1.15 | 0.622–2.137 | 0.651 | 0.983 | 0.576–1.676 | 0.950 | 0.922 | 0.513–1.657 | 0.786 |
| Oligoastrocytoma | 0.830 | 0.506–1.360 | 0.460 | 0.825 | 0.549–1.241 | 0.355 | 0.855 | 0.555–1.317 | 0.477 |
| % Ki67 | |||||||||
| ≤4 | 1 | 1 | 1 | ||||||
| >4 | 1.952 | 1.247–3.057 | 0.003 | 1.222 | 0.851–1.755 | 0.278 | 1.635 | 1.102–2.425 | 0.015 |
| Number of mitoses 10 HPF (modeled as continuous variable) | 1.052 | 0.924–1.198 | 0.442 | 1.042 | 0.927–1.171 | 0.496 | 1.037 | 0.922–1.166 | 0.541 |
| IDH1 or IDH2 mutation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.157 | 0.070–0.355 | <0.0001 | 0.348 | 0.160–0.756 | 0.008 | 0.235 | 0.106–0.518 | <0.0001 |
| Chromosome 1p/19q codeletion | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.710 | 0.453–1.112 | 0.134 | 0.671 | 0.462–0.973 | 0.035 | 0.579 | 0.385–0.869 | 0.008 |
| Molecular class | |||||||||
| IDH1/2 wild type | 1 | 1 | 1 | ||||||
| IDH1/2 mutant | 0.172 | 0.075–0.397 | <0.0001 | 0.399 | 0.181–0.878 | 0.022 | 0.283 | 0.127–0.631 | 0.002 |
| IDH1/2 mutant and 1p/19q codeletion | 0.136 | 0.057–0.324 | <0.0001 | 0.282 | 0.125–0.636 | 0.002 | 0.175 | 0.076–0.405 | <0.0001 |
| P53 expression (modeled as continuous variable) | 1.477 | 0.797–2.735 | 0.215 | 1.619 | 0.970–2.701 | 0.065 | 1.696 | 0.990–2.908 | 0.055 |
| ATRX downregulation | |||||||||
| Yes | 1 | 1 | 1 | ||||||
| No | 1.185 | 0.764–1.838 | 0.448 | 0.873 | 0.608–1.255 | 0.464 | 0.876 | 0.592–1.296 | 0.507 |
| MGMT promoter methylation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.525 | 0.227–1.213 | 0.132 | 0.858 | 0.399–1.846 | 0.695 | 0.771 | 0.337–1.763 | 0.537 |
| Total NF-κB/p65 (modeled as continuous variable) | 0.998 | 0.990–1.006 | 0.655 | 0.996 | 0.989–1.003 | 0.259 | 0.999 | 0.991–1.006 | 0.766 |
| Nuclear NF-κB/p65 (modeled as continuous variable) | 1.003 | 0.999–1.007 | 0.100 | 1.002 | 0.999–1.006 | 0.220 | 1.004 | 1.001–1.008 | 0.015 |
| . | OS . | PFS . | MPFS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Age (modeled as continuous variable) | 1.021 | 1.003–1.040 | 0.021 | 1.008 | 0.993–1.024 | 0.287 | 1.014 | 0.997–1.030 | 0.104 |
| Sex | |||||||||
| Male | 1 | 1 | 1 | ||||||
| Female | 0.706 | 0.446–1.120 | 0.139 | 0.906 | 0.627–1.309 | 0.600 | 0.718 | 0.480–1.073 | 0.106 |
| KPS (modeled as continuous variable) | 0.963 | 0.931–0.996 | 0.027 | 0.987 | 0.957–1.018 | 0.410 | 0.970 | 0.940–1.000 | 0.052 |
| Preoperative volume (T2_pre) (modeled as continuous variable) | 1.002 | 0.998–1.006 | 0.357 | 1.003 | 1.000–1.007 | 0.071 | 1.006 | 1.002–1.009 | 0.002 |
| Infiltrative growth index (T2_ T1) (modeled as continuous variable) | 1.028 | 1.014–1.043 | <0.0001 | 1.028 | 1.015–1.042 | <0.0001 | 1.038 | 1.024–1.053 | <0.0001 |
| Postoperative (T2_post) (modeled as continuous variable) | 1.007 | 0.998–1.015 | 0.112 | 1.007 | 1.001–1.015 | 0.030 | 1.017 | 1.010–1.024 | <0.0001 |
| % EOR (modeled as continuous variable) | 0.942 | 0.926–0.959 | <0.0001 | 0.955 | 0.941–0.970 | <0.0001 | 0.951 | 0.936–0.966 | <0.0001 |
| Histotype (WHO 2007) | |||||||||
| Astrocytoma | 1 | 1 | 1 | ||||||
| Oligodendroglioma | 1.15 | 0.622–2.137 | 0.651 | 0.983 | 0.576–1.676 | 0.950 | 0.922 | 0.513–1.657 | 0.786 |
| Oligoastrocytoma | 0.830 | 0.506–1.360 | 0.460 | 0.825 | 0.549–1.241 | 0.355 | 0.855 | 0.555–1.317 | 0.477 |
| % Ki67 | |||||||||
| ≤4 | 1 | 1 | 1 | ||||||
| >4 | 1.952 | 1.247–3.057 | 0.003 | 1.222 | 0.851–1.755 | 0.278 | 1.635 | 1.102–2.425 | 0.015 |
| Number of mitoses 10 HPF (modeled as continuous variable) | 1.052 | 0.924–1.198 | 0.442 | 1.042 | 0.927–1.171 | 0.496 | 1.037 | 0.922–1.166 | 0.541 |
| IDH1 or IDH2 mutation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.157 | 0.070–0.355 | <0.0001 | 0.348 | 0.160–0.756 | 0.008 | 0.235 | 0.106–0.518 | <0.0001 |
| Chromosome 1p/19q codeletion | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.710 | 0.453–1.112 | 0.134 | 0.671 | 0.462–0.973 | 0.035 | 0.579 | 0.385–0.869 | 0.008 |
| Molecular class | |||||||||
| IDH1/2 wild type | 1 | 1 | 1 | ||||||
| IDH1/2 mutant | 0.172 | 0.075–0.397 | <0.0001 | 0.399 | 0.181–0.878 | 0.022 | 0.283 | 0.127–0.631 | 0.002 |
| IDH1/2 mutant and 1p/19q codeletion | 0.136 | 0.057–0.324 | <0.0001 | 0.282 | 0.125–0.636 | 0.002 | 0.175 | 0.076–0.405 | <0.0001 |
| P53 expression (modeled as continuous variable) | 1.477 | 0.797–2.735 | 0.215 | 1.619 | 0.970–2.701 | 0.065 | 1.696 | 0.990–2.908 | 0.055 |
| ATRX downregulation | |||||||||
| Yes | 1 | 1 | 1 | ||||||
| No | 1.185 | 0.764–1.838 | 0.448 | 0.873 | 0.608–1.255 | 0.464 | 0.876 | 0.592–1.296 | 0.507 |
| MGMT promoter methylation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.525 | 0.227–1.213 | 0.132 | 0.858 | 0.399–1.846 | 0.695 | 0.771 | 0.337–1.763 | 0.537 |
| Total NF-κB/p65 (modeled as continuous variable) | 0.998 | 0.990–1.006 | 0.655 | 0.996 | 0.989–1.003 | 0.259 | 0.999 | 0.991–1.006 | 0.766 |
| Nuclear NF-κB/p65 (modeled as continuous variable) | 1.003 | 0.999–1.007 | 0.100 | 1.002 | 0.999–1.006 | 0.220 | 1.004 | 1.001–1.008 | 0.015 |
Boldface represents statistical significance values from 2-sided tests (Cox regression) statistically significant when <0.05.
Univariate analysis of clinical, histological, and molecular parameters with OS, PFS, and MPFS in 146 patients with low-grade-gliomas
| . | OS . | PFS . | MPFS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Age (modeled as continuous variable) | 1.021 | 1.003–1.040 | 0.021 | 1.008 | 0.993–1.024 | 0.287 | 1.014 | 0.997–1.030 | 0.104 |
| Sex | |||||||||
| Male | 1 | 1 | 1 | ||||||
| Female | 0.706 | 0.446–1.120 | 0.139 | 0.906 | 0.627–1.309 | 0.600 | 0.718 | 0.480–1.073 | 0.106 |
| KPS (modeled as continuous variable) | 0.963 | 0.931–0.996 | 0.027 | 0.987 | 0.957–1.018 | 0.410 | 0.970 | 0.940–1.000 | 0.052 |
| Preoperative volume (T2_pre) (modeled as continuous variable) | 1.002 | 0.998–1.006 | 0.357 | 1.003 | 1.000–1.007 | 0.071 | 1.006 | 1.002–1.009 | 0.002 |
| Infiltrative growth index (T2_ T1) (modeled as continuous variable) | 1.028 | 1.014–1.043 | <0.0001 | 1.028 | 1.015–1.042 | <0.0001 | 1.038 | 1.024–1.053 | <0.0001 |
| Postoperative (T2_post) (modeled as continuous variable) | 1.007 | 0.998–1.015 | 0.112 | 1.007 | 1.001–1.015 | 0.030 | 1.017 | 1.010–1.024 | <0.0001 |
| % EOR (modeled as continuous variable) | 0.942 | 0.926–0.959 | <0.0001 | 0.955 | 0.941–0.970 | <0.0001 | 0.951 | 0.936–0.966 | <0.0001 |
| Histotype (WHO 2007) | |||||||||
| Astrocytoma | 1 | 1 | 1 | ||||||
| Oligodendroglioma | 1.15 | 0.622–2.137 | 0.651 | 0.983 | 0.576–1.676 | 0.950 | 0.922 | 0.513–1.657 | 0.786 |
| Oligoastrocytoma | 0.830 | 0.506–1.360 | 0.460 | 0.825 | 0.549–1.241 | 0.355 | 0.855 | 0.555–1.317 | 0.477 |
| % Ki67 | |||||||||
| ≤4 | 1 | 1 | 1 | ||||||
| >4 | 1.952 | 1.247–3.057 | 0.003 | 1.222 | 0.851–1.755 | 0.278 | 1.635 | 1.102–2.425 | 0.015 |
| Number of mitoses 10 HPF (modeled as continuous variable) | 1.052 | 0.924–1.198 | 0.442 | 1.042 | 0.927–1.171 | 0.496 | 1.037 | 0.922–1.166 | 0.541 |
| IDH1 or IDH2 mutation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.157 | 0.070–0.355 | <0.0001 | 0.348 | 0.160–0.756 | 0.008 | 0.235 | 0.106–0.518 | <0.0001 |
| Chromosome 1p/19q codeletion | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.710 | 0.453–1.112 | 0.134 | 0.671 | 0.462–0.973 | 0.035 | 0.579 | 0.385–0.869 | 0.008 |
| Molecular class | |||||||||
| IDH1/2 wild type | 1 | 1 | 1 | ||||||
| IDH1/2 mutant | 0.172 | 0.075–0.397 | <0.0001 | 0.399 | 0.181–0.878 | 0.022 | 0.283 | 0.127–0.631 | 0.002 |
| IDH1/2 mutant and 1p/19q codeletion | 0.136 | 0.057–0.324 | <0.0001 | 0.282 | 0.125–0.636 | 0.002 | 0.175 | 0.076–0.405 | <0.0001 |
| P53 expression (modeled as continuous variable) | 1.477 | 0.797–2.735 | 0.215 | 1.619 | 0.970–2.701 | 0.065 | 1.696 | 0.990–2.908 | 0.055 |
| ATRX downregulation | |||||||||
| Yes | 1 | 1 | 1 | ||||||
| No | 1.185 | 0.764–1.838 | 0.448 | 0.873 | 0.608–1.255 | 0.464 | 0.876 | 0.592–1.296 | 0.507 |
| MGMT promoter methylation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.525 | 0.227–1.213 | 0.132 | 0.858 | 0.399–1.846 | 0.695 | 0.771 | 0.337–1.763 | 0.537 |
| Total NF-κB/p65 (modeled as continuous variable) | 0.998 | 0.990–1.006 | 0.655 | 0.996 | 0.989–1.003 | 0.259 | 0.999 | 0.991–1.006 | 0.766 |
| Nuclear NF-κB/p65 (modeled as continuous variable) | 1.003 | 0.999–1.007 | 0.100 | 1.002 | 0.999–1.006 | 0.220 | 1.004 | 1.001–1.008 | 0.015 |
| . | OS . | PFS . | MPFS . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Age (modeled as continuous variable) | 1.021 | 1.003–1.040 | 0.021 | 1.008 | 0.993–1.024 | 0.287 | 1.014 | 0.997–1.030 | 0.104 |
| Sex | |||||||||
| Male | 1 | 1 | 1 | ||||||
| Female | 0.706 | 0.446–1.120 | 0.139 | 0.906 | 0.627–1.309 | 0.600 | 0.718 | 0.480–1.073 | 0.106 |
| KPS (modeled as continuous variable) | 0.963 | 0.931–0.996 | 0.027 | 0.987 | 0.957–1.018 | 0.410 | 0.970 | 0.940–1.000 | 0.052 |
| Preoperative volume (T2_pre) (modeled as continuous variable) | 1.002 | 0.998–1.006 | 0.357 | 1.003 | 1.000–1.007 | 0.071 | 1.006 | 1.002–1.009 | 0.002 |
| Infiltrative growth index (T2_ T1) (modeled as continuous variable) | 1.028 | 1.014–1.043 | <0.0001 | 1.028 | 1.015–1.042 | <0.0001 | 1.038 | 1.024–1.053 | <0.0001 |
| Postoperative (T2_post) (modeled as continuous variable) | 1.007 | 0.998–1.015 | 0.112 | 1.007 | 1.001–1.015 | 0.030 | 1.017 | 1.010–1.024 | <0.0001 |
| % EOR (modeled as continuous variable) | 0.942 | 0.926–0.959 | <0.0001 | 0.955 | 0.941–0.970 | <0.0001 | 0.951 | 0.936–0.966 | <0.0001 |
| Histotype (WHO 2007) | |||||||||
| Astrocytoma | 1 | 1 | 1 | ||||||
| Oligodendroglioma | 1.15 | 0.622–2.137 | 0.651 | 0.983 | 0.576–1.676 | 0.950 | 0.922 | 0.513–1.657 | 0.786 |
| Oligoastrocytoma | 0.830 | 0.506–1.360 | 0.460 | 0.825 | 0.549–1.241 | 0.355 | 0.855 | 0.555–1.317 | 0.477 |
| % Ki67 | |||||||||
| ≤4 | 1 | 1 | 1 | ||||||
| >4 | 1.952 | 1.247–3.057 | 0.003 | 1.222 | 0.851–1.755 | 0.278 | 1.635 | 1.102–2.425 | 0.015 |
| Number of mitoses 10 HPF (modeled as continuous variable) | 1.052 | 0.924–1.198 | 0.442 | 1.042 | 0.927–1.171 | 0.496 | 1.037 | 0.922–1.166 | 0.541 |
| IDH1 or IDH2 mutation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.157 | 0.070–0.355 | <0.0001 | 0.348 | 0.160–0.756 | 0.008 | 0.235 | 0.106–0.518 | <0.0001 |
| Chromosome 1p/19q codeletion | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.710 | 0.453–1.112 | 0.134 | 0.671 | 0.462–0.973 | 0.035 | 0.579 | 0.385–0.869 | 0.008 |
| Molecular class | |||||||||
| IDH1/2 wild type | 1 | 1 | 1 | ||||||
| IDH1/2 mutant | 0.172 | 0.075–0.397 | <0.0001 | 0.399 | 0.181–0.878 | 0.022 | 0.283 | 0.127–0.631 | 0.002 |
| IDH1/2 mutant and 1p/19q codeletion | 0.136 | 0.057–0.324 | <0.0001 | 0.282 | 0.125–0.636 | 0.002 | 0.175 | 0.076–0.405 | <0.0001 |
| P53 expression (modeled as continuous variable) | 1.477 | 0.797–2.735 | 0.215 | 1.619 | 0.970–2.701 | 0.065 | 1.696 | 0.990–2.908 | 0.055 |
| ATRX downregulation | |||||||||
| Yes | 1 | 1 | 1 | ||||||
| No | 1.185 | 0.764–1.838 | 0.448 | 0.873 | 0.608–1.255 | 0.464 | 0.876 | 0.592–1.296 | 0.507 |
| MGMT promoter methylation | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.525 | 0.227–1.213 | 0.132 | 0.858 | 0.399–1.846 | 0.695 | 0.771 | 0.337–1.763 | 0.537 |
| Total NF-κB/p65 (modeled as continuous variable) | 0.998 | 0.990–1.006 | 0.655 | 0.996 | 0.989–1.003 | 0.259 | 0.999 | 0.991–1.006 | 0.766 |
| Nuclear NF-κB/p65 (modeled as continuous variable) | 1.003 | 0.999–1.007 | 0.100 | 1.002 | 0.999–1.006 | 0.220 | 1.004 | 1.001–1.008 | 0.015 |
Boldface represents statistical significance values from 2-sided tests (Cox regression) statistically significant when <0.05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
